Gc Pharma Remedies Profile
Key Indicators
- Authorised Capital ₹ 6.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.41 M
as on 17-07-2024
- Company Age 24 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.32 Cr
as on 17-07-2024
- Revenue %
(FY 2022)
- Profit 98.46%
(FY 2022)
- Ebitda 98.46%
(FY 2022)
- Net Worth -1.24%
(FY 2022)
- Total Assets -0.00%
(FY 2022)
About Gc Pharma Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.50 M and a paid-up capital of Rs 0.41 M.
The company has closed loans amounting to ₹1.32 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chandrashekhar Bohra and Gopal Agrawal serve as directors at the Company.
- CIN/LLPIN
U24230MH2000PTC127701
- Company No.
127701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Gc Pharma Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrashekhar Bohra  | Director | 14-Jul-2000 | Current |
| Gopal Agrawal | Director | 14-Jul-2000 | Current |
Financial Performance and Corporate Structure Insights of Gc Pharma Remedies.
Gc Pharma Remedies Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 98.46% increase in profit. The company's net worth dipped by a decrease of 1.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gc Pharma Remedies?
In 2023, Gc Pharma Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ambalal Sarabhai Enterprises LimitedActive 46 years 6 monthsChandrashekhar Bohra is a mutual person
Baidyanath Minerals Private LimitedActive 21 years 11 monthsChandrashekhar Bohra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 10 Sep 2004 | ₹1.32 Cr | Satisfied |
How Many Employees Work at Gc Pharma Remedies?
Unlock and access historical data on people associated with Gc Pharma Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gc Pharma Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gc Pharma Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
